Cell therapy with human reprogrammed CD8+ T-cells has antimetastatic effects on Lewis lung carcinoma in C57BL/6 mice

Эндаумент фонд ТГУ!
Впиши своё имя в историю университета
- Сделать пожертвование -

Add to "Quick Collection"

Description	Size	Format
Cell therapy with human reprogrammed CD8+ T-cells has antimetastatic effects on Lewis lung carcinoma in C57BL/6 mice	2 MB	Adobe Acrobat PDF	Read	Download
DOI Доступ к ресурсу на сайте издателя			10.3390/ijms232415780

Title: Cell therapy with human reprogrammed CD8+ T-cells has antimetastatic effects on Lewis lung carcinoma in C57BL/6 mice
Creator: Skurikhin, Evgenii G.
|
Pershina, Olga
|
Ermakova, Natalia N.
|
Pakhomova, Angelina
|
Zhukova, Mariia
|
Pan, Edgar S.
|
Sandrikina, Lubov
|
Widera, Darius
|
Kogai, Lena
|
Kushlinskii, Nikolai
|
Kubatiev, Aslan A.
|
Morozov, Sergey G.
|
Dygai, Alexander M.
Date: 2022
DOI: 10.3390/ijms232415780
Description: Using a model of Lewis lung carcinoma (LLC) in vitro and in vivo, we previously demonstrated increased antitumor activity in CD8+ T-cells reprogrammed with an MEK inhibitor and PD-1 blocker. In this follow-up study, we carried out the reprogramming of human CD8+ T-cells (hrT-cell) using the MEK inhibitor and PD-1 blocker and targeted LLC cells. The effects of hrT-cell therapy were studied in a mouse model of spontaneous metastasis of a solid LLC tumor. We found antimetastatic activity of hrT-cells, a decrease in the number of cancer cells and cancer stem cells in the lungs, and an increase in the number of T-cells in the blood (including effector T-cells). Thus, reprogramming of human CD8+ T-cells with an MEK inhibitor and PD-1 blocker with targeted training by tumor target cells is a potential platform for developing a new approach to targeted lung cancer therapy.